Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.
Age range: 18-75 years old (including both ends), gender is not limited.
Subjects with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or radiotherapy treatment
ECOG score is 0 or 1
Expected survival period ≥ 12 weeks
Suffering from other malignant tumors within the past 5 years
Subjects with active central nervous system (CNS) tumor metastasis, a history of meningeal metastasis, or current meningeal metastasis
Patients with uncontrollable tumor related pain
Has serious cardiovascular and cerebrovascular diseases